Copyright 2016 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.
In the Original Investigation entitled “Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma,” published in the April 19, 2016, issue of JAMA,1 article text was attributed to incorrect reference citations and 2 Figures were incorrectly labeled. In the Study Design and Conduct section, a phrase that reads “and a cohort that included both ipilimumab-naive10-13” should be attributed to references 10 and 11. In Figure 3 and Figure 5, the black line within the key should be labeled as “Total” and the blue line should be labeled as “Treatment naive.” This article was corrected online.
Incorrect Reference Citations and Figure Labeling. JAMA. 2016;315(22):2472. doi:10.1001/jama.2016.6779